Equity Details
Price & Market Data
Price: $2.05
Daily Change: -$0.15 / 7.32%
Daily Range: $2.05 - $2.26
Market Cap: $3,647,926
Daily Volume: 31,448
Performance Metrics
1 Week: 4.67%
1 Month: -15.15%
3 Months: -12.84%
6 Months: -96.08%
1 Year: -93.75%
YTD: -68.00%
About GRI Bio, Inc. (GRI)
Daily market data for GRI Bio, Inc. (GRI). Current price: 2.05, daily change: -$0.15 / 7.32%. Market cap: 3,647,926. Performance 1-week and 52-week.
Company Details
Employees: 4
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
